Can Remicade (infliximab) trigger a lupus-like syndrome?
Yes. Remicade (infliximab) can cause lupus-like reactions, which may include symptoms such as joint pain, rash, and other signs resembling lupus. These reactions are documented as part of the drug’s immune-mediated adverse effects profile.
What lupus-like symptoms are patients told to watch for?
Patients are typically advised to report new or worsening autoimmune-type symptoms, such as:
- Joint pain or swelling
- Skin rash (including rashes that resemble lupus)
- Unexplained fever, fatigue, or other systemic symptoms
The key point is that these lupus-like presentations can occur after starting treatment with TNF blockers like Remicade.
Why would Remicade lead to lupus-like disease?
Remicade is a TNF-alpha inhibitor. In some people, TNF blockade can shift immune signaling in a way that promotes autoantibody formation and lupus-like immune activity, leading to symptoms that resemble systemic lupus erythematosus.
Is this the same as true lupus (systemic lupus erythematosus)?
Not necessarily. “Lupus-like syndrome” refers to lupus-like clinical features (and sometimes autoantibodies) occurring in association with the drug. It can look similar to lupus, but the pattern can differ from classic idiopathic systemic lupus erythematosus.
What should you do if symptoms appear?
If someone develops lupus-like symptoms while on Remicade, they should contact their clinician promptly. Treatment may require stopping or adjusting infliximab depending on severity, and clinicians may order evaluation for lupus-like autoimmunity.
Source
No source was provided in the prompt for Remicade’s lupus-like syndrome information, so I can’t cite DrugPatentWatch.com or other references here. If you share the specific label text or a link you’re using, I can map it directly to the lupus-like syndrome question.